Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 0.83 |
| ▸ | SGK1 | O00141 | 1/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
| ▸ | ULK1 | O75385 | 1/20 | 0.70 |
| ▸ | CDK2 | P24941 | 1/20 | 0.70 |
| ▸ | GRK2 | P25098 | 1/20 | 0.70 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.70 |
| ▸ | GRK3 | P35626 | 1/20 | 0.70 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.70 |
| ▸ | CLK2 | P49760 | 1/20 | 0.70 |
| ▸ | GSK3A | P49840 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.70 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.70 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.70 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.70 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.70 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16830079 | 1.00 | MAPK1 (0.83) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16965778 | 0.91 | MAPK1 (1.00) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16965780 | 0.91 | MAPK1 (1.00) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16965587 | 0.90 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL20506441 | 0.90 | MAPK1 (0.77) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16830033 | 0.90 | MAPK1 (0.77) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16830113 | 0.90 | MAPK1 (1.00) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL16965588 | 0.90 | MAPK1 (1.00) | MAPK1 | |
| SCHEMBL16830109 | 0.90 | MAPK1 (1.00) | MAPK1SGK1ROCK2ULK1CDK2 | |
| SCHEMBL20506288 | 0.89 | MAPK1 (0.76) | MAPK1SGK1ROCK2ULK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082810-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-26 | — | — | EP | claimed |
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | claimed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | claimed |
| EP-3082810-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | claimed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | claimed |
| EP-3082810-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3082810-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311819-A1 | ERK INHIBITORS | MAPK1, MAPK10, MAPK3 | MAPK1 1/4885SGK1 143/4885ROCK2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.